FLASCO OncoPod

In this episode of the FLASCO OncoPod, Drew Piers, President of Sachs Media, explores the powerful role advocacy, storytelling, and strategic communications play in advancing cancer care beyond the clinic. Drawing on years of experience working alongside healthcare organizations and oncology professionals, Drew discusses how trusted clinician voices can influence public policy, improve patient access to care, and strengthen public confidence in the healthcare system.
Listeners will gain practical insights into communicating complex healthcare issues with clarity, combining patient stories with evidence-based data, and engaging policymakers in meaningful ways that drive positive change. Whether through community outreach, media engagement, or legislative advocacy, this episode highlights how every oncology professional can help shape the future of cancer care through authentic, patient-centered communication.
Sachs Health INFLUENCE INDEX: https://sachsmedia.com/wp-content/uploads/2026/05/SachsHEALTH-Influence-Index-2026.pdf

Hepatocellular carcinoma (HCC) continues to present unique challenges for oncology teams, requiring coordinated multidisciplinary care and an evolving understanding of both liver disease and cancer management. In this episode of the FLASCO OncoPod, Dr. Beau Bosko Toskich, MD, FSIR, Professor of Radiology, Medical Oncology, and Radiation Oncology and Director of Interventional Oncology at Mayo Clinic Comprehensive Cancer Center, provides a comprehensive overview of the modern HCC treatment landscape.
Dr. Toskich discusses the changing epidemiology of hepatocellular carcinoma, emphasizing the growing impact of metabolic-associated liver disease, the importance of early detection and surveillance, and opportunities for disease prevention. He explores how multidisciplinary collaboration—including hepatology, surgery, interventional radiology, medical oncology, and radiation oncology—has transformed patient care, while highlighting the expanding role of locoregional therapies, immunotherapy, transplant evaluation, and emerging combination treatment strategies. Listeners will gain practical insights into patient selection, downstaging approaches, and the latest advances that are reshaping outcomes for patients with HCC.
Whether you routinely manage liver cancer or simply want to stay current on one of oncology's fastest-evolving disease states, this episode offers valuable clinical perspectives on delivering personalized, multidisciplinary care for patients with hepatocellular carcinoma.

In this episode of the FLASCO OncoPod, Dr. McDonough moderates a discussion with Dr. Wenk, Dr. Glick, and Dr. Patel, of Florida Cancer Specialists & Research Institute on the evolving role of community oncology and how today's practices are delivering academic-level cancer care closer to home.
Together, they explore how community oncology has transformed over the past decade, highlighting advances in precision medicine, immunotherapy, clinical research, and innovative care models. The conversation examines how large practice networks maintain consistent, high-quality care while expanding access to cutting-edge therapies and clinical trials for patients across diverse communities.
From scaling innovation across a statewide network to bringing academic-level expertise closer to home, this episode offers valuable insights into the future of oncology care and the increasingly vital role community oncology plays in advancing cancer treatment, research, and patient outcomes.

In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.
In part 4, the panel examines the real-world barriers that continue to affect IHC testing, including variability in reflex testing, pathology workflows, tissue stewardship, and reporting consistency. Experts share practical strategies for improving communication between oncologists and pathologists, streamlining testing protocols, and ensuring patients receive timely, comprehensive biomarker evaluation. Looking ahead, the discussion explores how artificial intelligence, digital pathology, electronic medical record integration, and automated clinical trial matching may transform precision oncology while reinforcing that multidisciplinary collaboration remains essential to delivering high-quality, personalized cancer care. The episode concludes with key takeaways clinicians can implement to strengthen biomarker-driven decision-making in their own practices.

This podcast is being sponsored by Daiichi Sankyo.

In this episode of the FLASCO OncoPod, host Dr. Edgardo Santos, President of the Florida Society of Clinical Oncology (FLASCO), leads a multidisciplinary discussion on the evolving role of immunohistochemistry (IHC) in precision oncology. Joined by Dr. Lamees Saeed (Tampa General Hospital Cancer Institute), Dr. Jesus Fabregas (Memorial Cancer Institute), Dr. Ana Sandoval (Herbert Wertheim Cancer Institute at Baptist Health South Florida), and Dr. Nathalie McKenzie (AdventHealth Cancer Institute), the panel explores how IHC has evolved from a diagnostic tool into a critical component of biomarker-driven treatment selection.
The panel discusses how expanding biomarker indications are changing when and how testing is performed, from first-line diagnosis through disease progression. Experts explore the growing clinical importance of HER2-low and HER2-ultralow expression in breast cancer, the role of comprehensive biomarker testing in gynecologic malignancies, and how IHC and next-generation sequencing work together to guide personalized treatment strategies in thoracic oncology. The conversation also highlights the importance of standardized pathology reporting, multidisciplinary collaboration, and balancing timely treatment with the need for complete biomarker results to ensure patients receive the most appropriate targeted therapies.

This podcast is being sponsored by Daiichi Sankyo.